The treatment with antibody of TNF-alpha reduces the inflammation, necrosis and fibrosis in the non-alcoholic steatohepatitis induced by methionine- and choline-deficient diet.
To assess the effects of anti-TNF-alpha antibody (infliximab) in experimental steatohepatitis induced by methionine- and choline-deficient (MCD) diet. The study included thirty rats. One group received normal rat food, and two groups received MCD diet. The treatment group received a single dose intra-peritoneal infliximab (4 mg/kg), at week 8. MCD diet increased levels of AST, ALT, TNF-alpha, TGF-beta(1), tissue and plasma MDA (p < 0.05 for each). Moreover, it led to steatosis, ballooning degeneration, inflammation, fibrosis and increased actin expression, histopathologically (p < 0.05 for each). In this experimental steatohepatitis anti-TNF-alpha antibody decreased the levels of AST, ALT, TGF-beta(1) and plasma and tissue MDA (p < 0.05 for each). Moreover, inflammation, necrosis, actin expression and fibrosis decreased in anti-TNF-alpha group compared to placebo group (p < 0.05 for each). This study indicates that anti-TNF-alpha antibody is effective on necrosis, inflammation and fibrosis in the experimental model of non-alcoholic steatohepatitis, induced by MCD diet.
Koca
Suleyman Serdar
SS
Faculty of Medicine, Department of Internal Medicine and Rheumatology, Firat University, Elazig, Turkey. kocassk@yahoo.com
Bahcecioglu
Ibrahim Halil
IH
Poyrazoglu
Orhan Kursat
OK
Ozercan
Ibrahim Hanifi
IH
Sahin
Kazim
K
Ustundag
Bilal
B
D000199:Actins / Q000378:metabolism; D000410:Alanine Transaminase / Q000097:blood; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000494:pharmacology*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000494:pharmacology*; D001219:Aspartate Aminotransferases / Q000097:blood; D002796:Choline Deficiency / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D004032:Diet; D004195:Disease Models, Animal; D005234:Fatty Liver / Q000209:etiology / Q000473:pathology / Q000517:prevention & control*; D006505:Hepatitis / Q000209:etiology / Q000473:pathology / Q000517:prevention & control*; D000069285:Infliximab; D007274:Injections, Intraperitoneal; D008099:Liver / Q000187:drug effects / Q000201:enzymology / Q000473:pathology; D008103:Liver Cirrhosis / Q000209:etiology / Q000473:pathology / Q000517:prevention & control*; D008297:Male; D008315:Malondialdehyde / Q000378:metabolism; D008715:Methionine / Q000172:deficiency*; D009336:Necrosis; D051381:Rats; D013997:Time Factors; D053773:Transforming Growth Factor beta1 / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000276:immunology / Q000378:metabolism
D000199:Actins; D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D053773:Transforming Growth Factor beta1; D014409:Tumor Necrosis Factor-alpha; D008315:Malondialdehyde; D008715:Methionine; D000069285:Infliximab; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase